GlassScriptPhysician profile
Randolph W Evans
NPI 1780684076
$492,739.24
in general payments reported to CMS, 2019-2025
24 companies · $6,629 in 2025
The $6,629 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149K · 2020: $133K · 2021: $89K · 2022: $78K · 2023: $27K · 2024: $9,734 · 2025: $6,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $1,076 · Consulting Fee: $568 · Travel and Lodging: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,368.75 |
| Food and Beverage | $1,076.28 |
| Consulting Fee | $568.00 |
| Travel and Lodging | $149.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $176,658.90 | 2019-2024 | Kisunla, Emgality |
| Abbvie INC. | $112,359.30 | 2021-2025 | |
| Allergan, INC. | $88,646.77 | 2019-2022 | |
| Amgen INC. | $51,014.05 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $28,996.36 | 2019-2024 | Ajovy |
| Impel Pharmaceuticals INC. | $14,869.86 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $7,101.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $6,071.28 | 2019 | |
| Promius Pharma LLC | $3,094.47 | 2019 | |
| Lundbeck LLC | $1,877.69 | 2020-2024 | Vyepti |
| Avanir Pharmaceuticals, INC. | $1,125.00 | 2019 | |
| Genzyme Corporation | $236.38 | 2019-2021 | |
| Abbott Laboratories | $177.24 | 2019 | |
| Boston Scientific Corporation | $118.74 | 2019 | |
| Pfizer INC. | $75.15 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $65.95 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.25 | 2022 | |
| Impel Pharmaceuticals LLC | $50.08 | 2024-2025 | Trudhesa |
| Supernus Pharmaceuticals, INC. | $38.20 | 2019 | |
| Emd Serono, INC. | $33.17 | 2019-2022 | |
| Zyla Life Sciences, INC. | $29.12 | 2019 | |
| Collegium Pharmaceutical, INC. | $21.80 | 2022 | |
| Scilex Pharmaceuticals INC. | $16.44 | 2023 | Ztlido |
| Currax Pharmaceuticals LLC | $3.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.